In vitro and in vivo activities of new rifamycin derivatives against mycobacterial infections

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3229-3238

  Lounis, N ^a,c   Roscigno, G ^b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Mycobacterium avium infections; Refalazil; Rifabutin; Rifapentine; Tuberculosis

Indexed keywords

CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; PROTEINASE INHIBITOR; PYRAZINAMIDE; PYRROLE DERIVATIVE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; STREPTOMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG METABOLISM; DRUG TOLERABILITY; EXPERIMENTAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERURICEMIA; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FRANCE; HUMANS; META-ANALYSIS; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; RANDOMIZED CONTROLLED TRIALS; RIFAMPIN; SWITZERLAND; TUBERCULOSIS, PULMONARY;

EID: 4644364773     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383287     Document Type: Review

References (46)

1. Truffot-Pernot C, Giroir AM, Maury L, Grosset J. Etude des concentrations minima inhibitrices de rifabutine (Ansamycine LM 427) pour Mycobacterium tuberculosis, Mycobacterium xenopi et Mycobacterium avium-intracellulare. Rev Mal Resp 1988; 5: 401-6.
2. Hirata T, Saito H, Tomioka H, Sato K, Jidoi J, Hosoe K, et al. in vitro and in vivo activities of the benzoxazinorifamycin KRM-1641 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 2295-2303.
3. Ji B, Truffot-Pernot C, Lacroix C, Raviglione MC, O'Brien RJ, Olliaro P, et al. Effectiveness of rifampin, ritabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis 1993; 148: 1541-6.
4. Kelly BP, Furney SK, Jessen MT, Orme IM. Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1996; 40: 2809-12.
5. Reddy MV, Luna-Herrera J, Daneluzzi D, Gangadharam PRJ. Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. Tuber Lung Dis 1996; 77: 154-9.
6. Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992; 73: 33-8.
7. Gonzalez-Montaner LJ, Natal S, Yongchaiyud P, Olliaro P. Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis 1994; 75: 341-7.
8. Schwander S, Rusch-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, et al. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. Tuber Lung Dis 1995; 76: 210-8.
9. Narita M, Stambaugh JJ, Hollender ES, Jones D, Pitchenik AE, Ashkin D. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis. Clin Infect Dis 2000; 30: 779-83.
10. Heifets L. Microbiological aspects of rifapentine. Drugs of Today 1999; 35 (Suppl. D): 7-15.
11. Arioli V, Berti M, Carniti G, Randisi E, Rossi E, Scotti R. Antibacterial activity of DL473, a new semisynthetic rifamycin derivative. J Antibiot 1981; 34: 1026-29.
12. Dickinson JM, Mitchison DA. In Vitro activity of new rifamycins against rifampin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987; 68: 177-82.
13. Truffot-Pernot C, Grosset J, Bismuth R, Lecoeur H. Activité de la rifampicine administrée de manière intermittente et de la cyclopentyl rifamycine (ou DL 473) sur la tuberculose expérimentale de la souris. Rev Fr Mal Res 1983; 11: 875-82.
14. Daniel N, Lounis N, Ji B, O'Brien RJ, Vernon A, Geiter LJ, et al. Antituberculosis activity of once-weekly rifapentine containing regimens in mice. Long term effectiveness with 6- and 8- month treatment regimens. Am J Respir Crit Care 2002; 161: 1572-77.
15. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against M. tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-86.
16. He GJ. A comparative study of rifapentine treatment and three years of follow-up on initial pulmonary tuberculosis. Chung Hua Chieh Ho Ho Hu Hsi Tsa Chih 1993; 16: 73-76.
17. Tam CM, Chan SL, Lam CW, Dickinson JM, Mitchison DA. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-6.
18. Albrecht H, Horsburg CRJ, Vernon A. Clinical studies of rifapentine. Drugs of Today 1999; 35(Suppl. D): 29-43.
19. Vernon A, Burman W, Benator D, Khan A, Bozeman L for the tuberculosis Trials Consortium. Acquired rifamycin mono-resistance among patients with HIV-related tuberculosis treated with supervised once-weekly rifapentine and isoniazid. Lancet 1999; 353: 1843-47.
20. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial. Lancet 2002; 360: 528-34.
21. Dietze R, Teixeira L, Rocha LM, Palaci M, Johnson JL, Wells C, et al. Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 2001; 45: 1972-76.
22. Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI. Development potential of rifalazil. Expert Opin Investig Drugs 2003; 12: 255-71.
23. Klemens SP, Cynamon MH. Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1996; 40: 298-301.
24. Klemens SP, Grossi MA, Cynamon MH. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. Antimicrob Agents Chemother 1994; 38: 234-237.
25. Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampin against Mycobacterium avium complex. Tubercle 1988; 69: 187-192.
26. Gangadharam PRJ, Perumal VK, Podapati NR, Kesavalu L, Iseman MD. In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother 1988; 32: 1400-1403.
27. Ji B, Lounis N, Truffot-Pernot C, Grosset J. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother 1994; 38: 2521-2529.
28. Klemens SP and Cynamon MH. in vivo activities of newer rifamycin analogs against Mycobacterium avium infection. Antimicrob Agents Chemother 1991; 35; 2026-2030.
29. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Selection of clarithromycin-resistant Mycobacterium avium complex during combined therapy using the beige mouse model. Antimicrob Agents Chemother 1995 ; 39: 608-612.
30. Nightingale SD, Cameron DW, Gordin FM, Sullam PM, Cohn DL, Chaisson RE, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. NEJM 1993; 329: 828-833.
31. Dautzenberg B, Castellani P, Pellegrin JL, Vittecoq D, Truffot-Pernot C, Pirotta N, et al. Early bactericidal activity of rifabutin versus that of placebo in treatment of disseminated Mycobacterium avium complex bacteremia in AIDS patients. Antimicrob Agents Chemother 1996; 40: 1722-1725.
32. Dautzenberg B, Olliaro P, Ruf B, Esposito R, Opravil M, Hoy JF, et al. Rifabutin versus placebo in combination with three drugs in the treatment of nontuberculous mycobacterial infection in patients with AIDS. Clin Infect Dis 1996; 22: 705-8.
33. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. Clin Infect Dis 1997; 2: 621-9.
34. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991; 35: 1356-59.
35. Klemens SP, Cynamon MH. Activity of rifapentine against Mycobacterium avium infection in beige mice. J Antimicrob Chemother 1992; 29: 555-61.
36. Brown ST, Edwards FF, Bernard EM, Tong W, Armstrong D. Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. Antimicrob Agents Chemother 1993; 37: 392-402.
37. Tomioka H, Saito H, Sato K, Yamane T, Yamashita K, Hosoe K, et al. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1992; 36: 387-93.
38. Ji B, Lounis N, Truffot-Pernot C, Grosset J. How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? Antimicrob Agents Chemother 1996; 40: 437-42.
39. Emori M, Saito H, Sato K, Tomioka H, Setogawa T, Hidaka T. Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother 1993; 37: 722-28.
40. Heifets LB, Lindholm-Levy PJ, Flory MA. Bactericidal activity In Vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1990; 141: 626-30.
41. Dickinson JM and Mitchison DA. In Vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle 1987; 68: 183-93.
42. Ji B, Jiakun C, Xizhen L, Shiyu W, Guoxing N, Yuhong H, et al. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473. Inter J Lepr Other Mycobact Dis 1986; 54: 563-77.
43. Dhillon J, Dickinson JM, Guy A, Ng TK, Mitchison DA. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tubercle and Lung Disease 1992; 73: 116-23.
44. Danelishvilli L, Bermudez LE. Role of type 1 cytokines in host defense against Mycobacterium avium infection. Curr Pharm Design 2003; 9(1): 61-5.
45. Reuning U, Sperl S, Kopitz C, Kessler H, Kruger A, Schmitt M, et al. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Design 2003; 9(19): 1529-43.
46. Yanagihara K. Design of anti-bacterial drug and anti-mycobacterial drug for drug delivery system. Curr Pharm Design 2002; 8(6): 475-82.